Eligibility depends on medical history and provider evaluation
The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model (see Box 1) and as states contend with budget challenges and the federal Medicaid spending cuts in the 2025 reconciliation law
Our data delineate the therapeutic superiority of the di-agonist, GLP1/E, in the management of the metabolic alterations of PCOS, with beneficial effects also on ovarian function in our PCOS model of preserved ovulatory function
If youve tried every diet trick without lasting success, this may be the tool that finally works in your favor, not against inbuilt quirks of metabolism
2013;36(5):1396-1405 (Human)
Understanding Retatrutide: A Multi-Receptor Approach to Weight Management Retatrutide is an investigational weight loss treatment that has gained attention in clinical research for its potential in managing obesity and supporting overall metabolic health
